Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Serin

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2006
Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II studyP Piedbois, D Serin, F Priou, et al.
Bulletin Du Cancer|November 28, 2008
[Edifice program: analysis of screening exam practices for cancer in France]J-Y Blay, F Eisinger, O Rixe, et al.
European Journal of Cancer (Oxford, England : 1990)|February 16, 2000
Caring About Women and Cancer (CAWAC): a European survey of the perspectives and experiences of women with female cancersU Veronesi, S von Kleist, K Redmond, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 1996
Cancer genetics clinics: target population and consultees' expectationsC Julian-Reynier, F Eisinger, F Chabal, et al.
Journal of Medical Genetics|September 1, 1996
Attitudes towards cancer predictive testing and transmission of information to the familyC Julian-Reynier, F Eisinger, P Vennin, et al.
European Journal of Cancer (Oxford, England : 1990)|February 14, 2004
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancerP Fumoleau, R Largillier, C Clippe, et al.
British Journal of Cancer|October 20, 2011
High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancerE Brain, C Levy, D Serin, et al.
Annales D'Endocrinologie|March 10, 2001
[Patient information. Guidelines for practitioners - March 2000]P Bail, P Bizel, J Bonnard, et al.
Critical Reviews in Oncology/Hematology|May 16, 2009
Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 casesB Cutuli, C Cohen-Solal Le-Nir, D Serin, et al.
Presse Medicale (Paris, France : 1983)|February 25, 2000
[Leukemia and pre-leukemic conditions occurring after treatment of breast cancer]B Cutuli, M Janvier, A de la Rochefordière, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2006
Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II studyP Piedbois, D Serin, F Priou, et al.
Bulletin Du Cancer|November 28, 2008
[Edifice program: analysis of screening exam practices for cancer in France]J-Y Blay, F Eisinger, O Rixe, et al.
European Journal of Cancer (Oxford, England : 1990)|February 16, 2000
Caring About Women and Cancer (CAWAC): a European survey of the perspectives and experiences of women with female cancersU Veronesi, S von Kleist, K Redmond, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 1996
Cancer genetics clinics: target population and consultees' expectationsC Julian-Reynier, F Eisinger, F Chabal, et al.
Journal of Medical Genetics|September 1, 1996
Attitudes towards cancer predictive testing and transmission of information to the familyC Julian-Reynier, F Eisinger, P Vennin, et al.
European Journal of Cancer (Oxford, England : 1990)|February 14, 2004
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancerP Fumoleau, R Largillier, C Clippe, et al.
British Journal of Cancer|October 20, 2011
High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancerE Brain, C Levy, D Serin, et al.
Annales D'Endocrinologie|March 10, 2001
[Patient information. Guidelines for practitioners - March 2000]P Bail, P Bizel, J Bonnard, et al.
Critical Reviews in Oncology/Hematology|May 16, 2009
Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 casesB Cutuli, C Cohen-Solal Le-Nir, D Serin, et al.
Presse Medicale (Paris, France : 1983)|February 25, 2000
[Leukemia and pre-leukemic conditions occurring after treatment of breast cancer]B Cutuli, M Janvier, A de la Rochefordière, et al.
Pageof 7